Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range

Paris, france / accesswire / october 18, 2023 / abivax sa (euronext paris: fr0012333284 - abvx) ("abivax" or the "company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced the formal commencement of book-building and the filing of an amended registration statement on form f-1, including an estimated initial public offering price range, in connection with its intention to issue, subject to market and other conditions, approximately 20,325,500 ordinary shares (including ordinary shares in the form of american depositary shares ("adss")) of the company in an initial public offering of adss, each representing one ordinary share, in the united states (the "u.s. offering") and a concurrent offering of ordinary shares in certain jurisdictions outside of the united states (the "european private placement", and together, the "global offering"). abivax intends to grant the underwriters (the "underwriters") a 30-day option to purchase additional adss and/or ordinary shares in an aggregate amount of up to 15% of the total number of adss and ordinary shares proposed to be sold in the global offering.
ABVX Ratings Summary
ABVX Quant Ranking